Phase II study of carboplatin/nab-paclitaxel/atezolizumab combination therapy for advanced nonsquamous non–small cell lung cancer patients with impaired renal function: RESTART trial

Phase II study of carboplatin/nab-paclitaxel/atezolizumab combination therapy for advanced nonsquamous non–small cell lung cancer patients with impaired renal function: RESTART trial

Abstract Background  First-line treatment of nonsquamous non–small cell lung cancer (NSCLC) has undergone a paradigm shift to platinum combination therapy together with immune checkpoint inhibitors (ICIs). However, phase III studies of combinations of cytotoxic chemotherapy and ICIs have included on...

Full description

Bibliographic Details
Main Authors: Yoshimasa Shiraishi, Junji Kishimoto, Takayuki Shimose, Yukihiro Toi, Shunichi Sugawara, Isamu Okamoto
Format: Article
Language:English
Published: BMC 2022-09-01
Series:BMC Cancer
Subjects:
Clinical trial
Nonsquamous non–small cell lung cancer
Immune checkpoint inhibitor
Chemotherapy
Renal impairment
Online Access:https://doi.org/10.1186/s12885-022-10056-x

Internet

https://doi.org/10.1186/s12885-022-10056-x

Similar Items